Esperoct is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in adults and children with factor VIII deficiency due to hemophilia A. Esperoct can also be used for routine prophylaxis. The technical name of Esperoct is Antihemophilic factor [recombinant], glycopegylated-exei.
Esperoct is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.
How do I take it?
Prescribing information states that Esperoct is given as an intravenous injection.
Esperoct comes as a powder that must be reconstituted before injection.
The FDA-approved label for Esperoct lists common side effects including rash, redness, itching, and injection site reactions.
Rare but serious side effects listed for Esperoct include hypersensitivity reactions and the development of inhibitors.
For more details about this treatment, visit:
Esperoct - Novo Nordisk
Treatment of Hemophilia– Hemophilia Federation of America